AK112 + chemotherapy before surgery for triple-negative breast cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs—AK112 (an immunotherapy) and nab-paclitaxel plus carboplatin (chemotherapy)—given before surgery to shrink or eliminate triple-negative breast cancer. The goal is to see if this approach can improve outcomes for patients with this aggressive type of breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have been diagnosed with triple-negative breast cancer (tests show it is negative for estrogen, progesterone, and HER2 receptors).
- Your cancer is at a stage where it can be surgically removed (T1-4, N0-3, M0), but not the smallest type (T1N0M0).
- You have at least one tumor that can be measured on scans.
- You have not previously received any cancer treatment (like chemotherapy, radiation, or immunotherapy) for this cancer.
- You have not been treated with a PD-1 or PD-L1 inhibitor before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called AK112 combined with chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if AK112 works better than a placebo at shrinking tumors and helping people live longer.
This trial tests a combination of stereotactic body radiation therapy (SBRT), chemotherapy, and an immunotherapy drug called AK104 given before surgery to treat triple-negative breast cancer. It aims to see if this approach can shrink tumors more effectively and help patients avoid a mastectomy.
This trial compares two different chemotherapy combinations given before surgery (neoadjuvant therapy) for people with triple-negative breast cancer. It looks to see which drug combination works better to control the cancer before and around the time of the operation.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin + paclitaxel) before surgery can improve outcomes for people with early-stage triple-negative breast cancer. It aims to shrink the tumor and increase the chance of a complete response.
Hear when a new Breast Cancer Female trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.